Roche Licenses First-in-Class Treatments for Chronic Pain to Afferent Pharmaceuticals; Afferent Secures $23 Million in Series A Financing Pappas, Third Rock, Domain and New Leaf Launch New Company ...

- Neuroscience Industry Veteran to Lead Development of Chronic Pain Treatments; Technology Targets Novel Biological Pathway - PALO ALTO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals, a ...

New company raised $23 million in a Series A financing round. A new company Afferent Pharmaceuticals has been founded with $23 million in Series A funding to develop new treatments for chronic pain ...

Novartis said that current CEO and chairman Daniel Vasella will hand over the chief-executive role to Joe Jimenez, who currently heads the company’s pharmaceuticals division, effective February 1.